The antinociceptive effect of fluvoxamine

Area of Science:

• Neuroscience
• Pharmacology
• Pain Management

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are primarily used for depression.
• The analgesic potential of SSRIs, including fluvoxamine, is an area of ongoing research.
• Understanding the interaction of fluvoxamine with opioid receptors is crucial for pain management strategies.

Purpose of the Study:

• To evaluate the antinociceptive (pain-relieving) effects of fluvoxamine.
• To investigate the interaction between fluvoxamine and different opioid receptor subtypes.
• To determine the mechanism of action underlying fluvoxamine's antinociceptive effects.

Main Methods:

• Antinociceptive effects were assessed in male ICR mice using a hotplate analgesia meter.
• Fluvoxamine was administered via intraperitoneal (i.p.), intrathecal (i.t.), and intracerebroventricular (i.c.v.) routes.
• The effect of naloxone (an opioid antagonist) and co-administration with opioid receptor agonists were examined.

Main Results:

• Fluvoxamine produced a dose-dependent antinociceptive effect across all tested administration routes.
• Naloxone did not inhibit the antinociceptive effect of fluvoxamine, suggesting a non-opioid mechanism.
• Fluvoxamine potentiated analgesia induced by agonists of kappa(3)-, mu-, delta-, and kappa(1)-opioid receptors, most significantly at kappa(3).

Conclusions:

• Fluvoxamine possesses intrinsic antinociceptive properties mediated through a non-opioid pathway.
• Fluvoxamine's ability to potentiate opioid analgesia suggests a potential role in combination pain therapy.
• Low-dose co-administration of fluvoxamine with opioids may offer a novel approach to pain management.